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Abstract
Background: In many HIV programmes in Africa, patients are assessed clinically and prepared for
antiretroviral treatment over a period of 4–12 weeks. Mortality rates following initiation of ART
are very high largely because patients present late with advanced disease. The rates of mortality
and retention during the pre-treatment period are not well understood. We conducted an
observational study to determine these rates.
Methods: HIV-infected subjects presenting at The AIDS Support Clinic in Jinja, SE Uganda, were
assessed for antiretroviral therapy (ART). Eligible subjects were given information and counselling
in 3 visits done over 4–6 weeks in preparation for treatment. Those who did not complete
screening were followed-up at home. Survival analysis was done using poisson regression.
Results: 4321 HIV-infected subjects were screened of whom 2483 were eligible for ART on
clinical or immunological grounds. Of these, 637 (26%) did not complete screening and did not start
ART. Male sex and low CD4 count were associated independently with not completing screening.
At follow-up at a median 351 days, 181 (28%) had died, 189 (30%) reported that they were on ART
with a different provider, 158 (25%) were alive but said they were not on ART and 109 (17%) were
lost to follow-up. Death rates (95% CI) per 100 person-years were 34 (22, 55) (n.18) within one
month and 37 (29, 48) (n.33) within 3 months. 70/158 (44%) subjects seen at follow-up said they
had not started ART because they could not afford transport.
Conclusion: About a quarter of subjects eligible for ART did not complete screening and pre-
treatment mortality was very high even though patients in this setting were well informed. For
many families, the high cost of transport is a major barrier preventing access to ART.
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Background
Antiretroviral therapy has been scaled-up rapidly in Africa
and elsewhere [1]. Early reports suggest that mortality of
HIV-infected on ART is typically between about 6 to 12
deaths per 100 person-years [2-7], which is substantially
better than in the pre-ART era [8] but higher than in devel-
oped countries [6]. One reason for the higher mortality in
Africa is that patients in Africa present late for treatment,
typically at 100–150 × 106/l CD4 cell count lower than in
developed countries and with advanced disease [9]. Mor-
tality in Africa is especially high during the first year after
initiation of ART[10]. Retention of subjects in ART pro-
grammes in Africa is also relatively low [11], suggesting
that the burden of mortality is underestimated in some
settings.
In many programmes in Africa, patients are assessed clin-
ically and prepared for treatment over a period of 4–12
weeks [9,12]. They typically attend clinic on three occa-
sions when information and counselling is provided on
adherence and other aspects of ART. Pre-treatment mor-
tality of around 30 deaths per 100 person-years has been
reported from 2 studies in South Africa [13-15], but very
little is known about rates of mortality elsewhere or
patient retention around this time, especially in routine
service delivery settings. We report the findings of a study
which screened over 4000 subjects for ART and estab-
lished survival rates and other outcomes among the sub-
jects who were eligible for ART but dropped out of the
programme and did not start treatment.
Methods
The study was conducted at The AIDS Support Organisa-
tion (TASO) clinic in Jinja, SE Uganda. TASO is a large
non-governmental organisation with 11 centres in the
country offering counselling, social and clinical services to
HIV-infected subjects.
The clinic in Jinja serves a predominantly rural/semi-
urban population up to a radius of about 100 kilometres.
Treatment and care are provided free and patients are
managed according to national health service guidelines.
TASO began providing information about ART to its cli-
ents around the end 2003, mostly through group meet-
ings and drama shows. Patients were screened for
eligibility from August 2004 and the first patients began
treatment about 4 weeks later. Recruitment into the pro-
gramme ended in December 2006 when the funds availa-
ble at that time had been used up. TASO was by far the
largest provider of ART in the region. Patients who had
been with the organisation the longest were given priority
during the first year of the programme and thereafter ART
was made available to all on a first come first served basis.
Assessment for ART was done over 3 visits to clinic which
were usually spread over 4–8 weeks. At the first visit,
patients were examined clinically and blood was taken
and sent for CD4 count testing. Information and counsel-
ling were provided on ART focussing on adherence, side-
effects, drug sharing, safer sexual behaviour, and was done
both one-to-one and in groups. The second appointment
was usually 2 weeks later. Those at WHO stage III (chronic
fever of unknown origin, chronic diarrhoea of unknown
origin, oral hairy leukoplakia and pyomyositis), stage IV,
or with CD4 count less 200 × 106/l were considered eligi-
ble for ART. Counselling was repeated and patients were
asked to return for a 3rd visit approximately 2 weeks later.
They were also asked to identify a medicine companion
who could provide support and reminders about drug tak-
ing. Between the 2nd and 3rd visit, case-conferences were
held by TASO clinical and counselling staff. Patients' read-
iness for ART as well as their clinical eligibility was re-
assessed and a decision was taken whether or not to pro-
vide ART. It was then at the 3rd visit that ART was offered
(following further information and patient counselling).
The first line regimen comprised either zidovudine or sta-
vudine, lamivudine, and either nevirapine or efavirenz.
Those who were not eligible for ART (at the second visit)
were provided counselling and asked to return to clinic
every 3–6 months for monitoring.
Patients who completed the screening and started on ART
after February 2005 were invited to join a cluster ran-
domised trial comparing different ART delivery strategies,
which was co-ordinated from the study site [12,16,17].
The trial was done under normal programme conditions
with TASO staff responsible for patient screening before
and patient management during the trial whilst a team of
independent research staff documented trial outcomes.
Trial and non-trial subjects were managed identically and
for example no incentives were given either to staff or
patients.
The data presented here refer to the screening period
before ART initiation and were collected to inform TASO
services. Follow-up of subjects who were eligible for ART
but dropped out of the programme and did not initiate on
ART at TASO Jinja was done between June 2007 and
December 2007. We ascertained survival status and if
alive, whether or not the subject was on ART from a differ-
ent provider. Visits were done by trained field officers.
Deaths were verified by close family members. Subjects
not found at home were visited again at least once.
Distributions of sex, age and CD4 count categories were
compared between groups using a chi-squared test. Com-
parions of CD4 count continuous data were compared
using the Kruskall-Wallis test. Factors associated withBMC Public Health 2009, 9:290 http://www.biomedcentral.com/1471-2458/9/290
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completing three screening visits and starting ART were
investigated by fitting logistic regression models. The
analysis of survival time (time to death or date last seen
alive) was investigated using survival analysis methods,
with the survival time being described using a Kaplan
Meier plot and summarized using mortality rates and inci-
dence rates for a composite endpoint of mortality or loss-
to-follow-up. The effect of CD4 count on mortality was
investigated by fitting Poisson regression models. All anal-
yses were done using Stata release 10.0.
Results
Baseline characteristics
4321 subjects (74% women, 26% men) had an initial
screen for eligibility for ART between September 04 and
December 06. The median (IQR) CD4 cell count × 106/l
was 138 (78 to 286) between September 04 and Decem-
ber 04, 157 (69 to 305) between January 05 and Decem-
ber 05 and 222 (111 to 388) between January 06 and
December 06. Overall, 1811 (42%) were at WHO clinical
stage III or IV and 2267 (52%) had CD4 count < 200 ×
106/l; 2483 (57%) were eligible for ART either on clinical
grounds or because they had CD4 count < 200 × 106/l.
Only 2182/2483 (88%, 95% CI 87, 89) of subjects eligi-
ble for ART returned for a second visit and were informed
of their eligibility for ART. The median time between the
first and second visits was 14 days (IQR 14 to 21). 1846/
2483 (74%, 95% CI 73 to 76%) of the eligible subjects
returned for a third visit and started ART. The median
interval between the initial screening and 3rd visit was 33
(range 15 to 406) days. The median (IQR) baseline CD4
count (cells per 106/l) of those who did not complete
screening was 87 (25 to 149) compared with 116 (46 to
170) for those who completed screening (p < 0.001, Wil-
coxon test) (Table 1). Male sex and low baseline CD4
count were associated independently with not completing
screening; there was no association between age or WHO
stage and screening completion (Table 1). The proportion
eligible for treatment who did not complete screening
increased over time: it was 50/304 (16%) between Sep-
tember 04 and December 04, 157/737 (21%) between
January 05 and December 05 and 430/1442 (30%)
between January 06 and December 06.
Survival status of 637 subjects eligible for ART who did not 
complete screening
Subjects were followed-up at home to ascertain their sur-
vival status a median 351 (IQR 183 to 518) days from the
first screening visit. One hundred and eighty-one (28%)
had died, 189 (30%) reported they were now on ART but
with a different provider, 158 (25%) were alive and but
not on ART because of their choosing and 109 (17%) were
lost to follow-up (Table 2) (Figure 1). Age and sex were
not associated significantly with follow-up status but
there were striking differences in baseline CD4 count:
those who died or were lost to follow-up had substantially
lower median CD4 counts than those who were alive and
either not on ART or receiving this from another provider
(Table 2).
The mortality rate was 27 per 100 person-years (95% CI
23–31), while the rate for the composite endpoint of mor-
tality or loss-to-follow-up was 43 per 100 person-years
Table 1: Baseline characteristics of the subjects who completed screening over 3 visits and started on ART and those who did not
Completed 3 screening visits and started ART Odds ratio (95% CI) for not completing screening
No
(n. 637)
Yes
(n. 1846)
Univariate Multivariate *
Men 211 (29) 520 (71) 1.26 (1.04, 1.54) 1.28 (1.05, 1.56)
women 426 (24) 1,326 (76) 1.0 1.0
(p = 0.02) (p = 0.02)
Age, years
<33 213 (28) 538 (72) 1.23 (0.98, 1.53) 1.20 (0.95, 1.51)
33–39 183 (25) 561 (75) 1.01 (0.81, 1.27) 1.22 (0.98, 1.53)
≥ 40 241 (24) 747 (76) 1.0 1.0
(p = 0.1) (p = 0.2)
CD4 count × 106/l
<50 232 (32) 485 (68) 1.72 (1.40, 2.12) 1.31 (1.0, 1.71)
50–99 114 (27) 314 (73) 1.31(1.01, 1.69) 1.68 (1.37, 2.06)
≥100 291 (22) 1047 (78) 1.0 1.0
(p < 0.0001) (p < 0.001)
WHO stage n = 628 n = 1842
I, II 265 (24) 830 (76) 0.89 (0.74, 1.07) -
III, IV 363 (26) 1,012 (74) 1.0
Note: WHO stage was not significant in multivariate analysis (p = 0.5) and not included in the final model.
* adjusted for sex and age and WHO categoryBMC Public Health 2009, 9:290 http://www.biomedcentral.com/1471-2458/9/290
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(95% CI 38–48). The rate ratios (95% CI) relative to sub-
jects with CD4 count × 106/l ≥100 were 2.82 (2.0, 4.0)
among subjects with CD4 count <50 × 106/l and 1.59
(1.0, 2.52) among subjects with CD4 count 50–99 × 106/
l. When stratified by calendar time, the mortality rates
(95% CI) per 100 person-years were 34 (22, 55) (n.18)
within one month, 37 (29, 48) (n.33) within 3 months,
35 (28, 42) (n. 97) within 6 months and 28 (24, 33) (n.
133) within 12 months.
Table 3 shows the reasons why the 158 subjects who were
eligible for ART, did not start treatment and were traced at
follow-up. Forty-four percent said that they did not start
treatment because they could not afford transport costs.
Just 4% reported difficulty in disclosure and declined to
start ART for this reason.
Discussion
Our study was conducted in a predominantly rural popu-
lation which had been sensitised and was eagerly awaiting
the introduction of ART. We found that a quarter of sub-
jects did not complete screening with the service provider
and did not initiate on ART. Of these, about half came
once and never returned while half came for a second
visit, were informed of their eligibility but despite learn-
ing this did not return again. The mortality rate during the
screening procedures was very high, about 35 deaths per
100 person-years in the first month and similarly high
shortly thereafter. This is consistent with findings from
Cape Town, South Africa, where pre-treatment mortality
was 30 deaths per 100-person-years [14,15]. In our study,
about 17% of the subjects who had not completed screen-
ing could not be traced and they also had very low CD4
count at their first screening visit. This suggests that our
pre-treatment mortality rate is probably an underestimate
as many of these subjects may have died before they could
access treatment elsewhere.
One major contributory factor to the high pre-treatment
mortality is patients presented at an advanced HIV stage
when serious co-morbidity is present, with low CD4
count, typically 100–150 cells per microlitre below when
treatment is recommended. Not only is pre-treatment
mortality high among such subjects, mortality shortly
after ART initiation is also very high [10] and a major pub-
lic health burden. Median CD4 counts of subjects at first
presentation increased over the 29 months of screening
during the study, suggesting that patients may have started
to present at an earlier stage; however, the proportion of
subjects eligible for ART who did not complete screening
also increased, rising from 21% in 2004 to 30% in 2006.
The reasons for this increase over time in the number who
did not complete screening are unclear but it is possible
that earlier patients were more motivated or that more
recently there was a greater choice of service providers
Kaplan-Meier survival curve of 637 subjects who were eligi- ble for antiretroviral therapy but did not complete screening  and did not start on antiretrovirals at the TASO Jinja clinic Figure 1
Kaplan-Meier survival curve of 637 subjects who were 
eligible for antiretroviral therapy but did not com-
plete screening and did not start on antiretrovirals at 
the TASO Jinja clinic.
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Table 2: Factors associated with outcomes among 637 subjects who did not complete screening and did not start antiretroviral 
therapy despite being eligible for treatment on clinical grounds
Died On ART with another provider Alive and not on ART Lost to follow-up p-value
(n. 181) (n. 189) (n. 158) (n. 109)
Male, number (%) 68 (38) 65 (34) 47 (30) 31 (28) 0.3 *
Age ≤ 35 years, number (%) 81 (45) 91 (48) 72 (46) 63 (58) 0.15*
CD4 count × 106/l
Median (IQR) 38 (8, 102) 105 (37, 162) 129 (77, 172) 67 (10, 127) 0.0001†
<50 104 (57) 53 (28) 25 (16) 50 (46) < 0.0001 *
50–99 30 (17) 37 (20) 29 (19) 18 (17)
≥100 47 (26) 99 (52) 104 (66) 41 (38)
* chi-squared test
† kruskall-wallis testBMC Public Health 2009, 9:290 http://www.biomedcentral.com/1471-2458/9/290
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available and TASO patients left to join other pro-
grammes. What is clear is that mortality during screening
is very high, especially among those presenting with low
CD4 count.
About a third of subjects who did not complete screening
were alive when they were followed-up at home about a
year later. The median CD4 count at screening, which was
done about one year earlier, was the highest among this
group although still low at a median 129 × 106/l CD4 cell
counts and well below the target CD4 count for initiating
ART. A staggering 44% of these said that they did not start
ART because they were unable to afford transport fare.
Our other research in this population suggests that family
cash incomes are low, typically less than 10 Euros a
month, and transport costs high, typically around 0.5 to 1
Euro each visit [12]. Thus costs are a major barrier for
patients accessing long-term chronic care from rural set-
tings such as ours. These must be taken into account in
efforts to expand access to ART and sustain adherence. For
this reason, one of TASO's strategies includes home based
delivery of ART but this involves substantial costs for the
provider and may not be sustainable or feasible in other
parts of Africa. A proportion of those who died are likely
to have had difficulty in accessing care because of costs
and so we have probably underestimated the burden of
high transport costs. Sustaining effective delivery of treat-
ment to such populations and ensuring regular contact
with health service staff to monitor and re-enforce adher-
ence will be a major challenge. A strategy may be to estab-
lish outreach services for patient monitoring and drug
refills that are delivered by skilled paramedical workers at
larger rural centres sufficiently close to the communities
where patients live. However, whether this could be effec-
tive needs evaluation.
In our setting, and indeed in other parts of Uganda, dis-
closure does not appear to be a major barrier to accessing
treatment [12]. TASO provides assistance to patients to
disclose where necessary and consequently just 4% of
those not on ART said that this was because they had dif-
ficulty disclosing. We know in this and other settings in
Uganda that fewer men than women are on antiretroviral
treatment [12,18]. In this study, among those who had
come forward to the health service, men were about 30%
less likely to complete screening as women. The reasons
for this are unclear and warrants investigation in this set-
ting.
Conclusion
This study shows that about a quarter of subjects eligible
for ART did not complete screening and did not initiate on
ART. The mortality rate was very high during the pre-treat-
ment period. Almost half of those still alive at the follow-
up visit said they had not completed screening because
they could not afford the transport costs to come to the
clinic. For many families, the high cost of transport is a
major barrier preventing access to ART.
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